» Articles » PMID: 38773273

Py-CoMFA, Docking, and Molecular Dynamics Simulations of Leishmania (L.) Amazonensis Arginase Inhibitors

Overview
Journal Sci Rep
Specialty Science
Date 2024 May 21
PMID 38773273
Authors
Affiliations
Soon will be listed here.
Abstract

Leishmaniasis is a disease caused by a protozoan of the genus Leishmania, affecting millions of people, mainly in tropical countries, due to poor social conditions and low economic development. First-line chemotherapeutic agents involve highly toxic pentavalent antimonials, while treatment failure is mainly due to the emergence of drug-resistant strains. Leishmania arginase (ARG) enzyme is vital in pathogenicity and contributes to a higher infection rate, thus representing a potential drug target. This study helps in designing ARG inhibitors for the treatment of leishmaniasis. Py-CoMFA (3D-QSAR) models were constructed using 34 inhibitors from different chemical classes against ARG from L. (L.) amazonensis (LaARG). The 3D-QSAR predictions showed an excellent correlation between experimental and calculated pIC values. The molecular docking study identified the favorable hydrophobicity contribution of phenyl and cyclohexyl groups as substituents in the enzyme allosteric site. Molecular dynamics simulations of selected protein-ligand complexes were conducted to understand derivatives' interaction modes and affinity in both active and allosteric sites. Two cinnamide compounds, 7g and 7k, were identified, with similar structures to the reference 4h allosteric site inhibitor. These compounds can guide the development of more effective arginase inhibitors as potential antileishmanial drugs.

Citing Articles

In silico evaluation of N-aryl-1,10-phenanthroline-2-amines as potential inhibitors of T. cruzi GP63 zinc-metalloprotease by docking and molecular dynamics simulations.

Camargo P, da Silva R, Zuma A, Garden S, Albuquerque M, Rodrigues C Sci Rep. 2025; 15(1):6036.

PMID: 39971997 PMC: 11839977. DOI: 10.1038/s41598-025-90088-y.


Exploring the Potential of Malvidin and Echiodinin as Probable Antileishmanial Agents Through In Silico Analysis and In Vitro Efficacy.

Goyzueta-Mamani L, Pagliara Lage D, Barazorda-Ccahuana H, Paco-Chipana M, Candia-Puma M, Davila-Del-Carpio G Molecules. 2025; 30(1.

PMID: 39795229 PMC: 11722285. DOI: 10.3390/molecules30010173.


In vitro assays identified thiohydantoins with anti-trypanosomatid activity and molecular modelling studies indicated possible selective CYP51 inhibition.

Camargo P, Suzukawa H, Pereira P, Silva M, Macedo Jr F, Albuquerque M Sci Rep. 2025; 15(1):465.

PMID: 39748011 PMC: 11695927. DOI: 10.1038/s41598-024-84697-2.

References
1.
Bagchi S, Chhibber T, Lahooti B, Verma A, Borse V, Jayant R . In-vitro blood-brain barrier models for drug screening and permeation studies: an overview. Drug Des Devel Ther. 2019; 13:3591-3605. PMC: 6805046. DOI: 10.2147/DDDT.S218708. View

2.
da Silva E, Brogi S, Lucon-Junior J, Campiani G, Gemma S, do Carmo Maquiaveli C . Dietary polyphenols rutin, taxifolin and quercetin related compounds target Leishmania amazonensis arginase. Food Funct. 2019; 10(6):3172-3180. DOI: 10.1039/c9fo00265k. View

3.
Muratov E, Bajorath J, Sheridan R, Tetko I, Filimonov D, Poroikov V . QSAR without borders. Chem Soc Rev. 2020; 49(11):3525-3564. PMC: 8008490. DOI: 10.1039/d0cs00098a. View

4.
de Lima E, Castelo-Branco F, Maquiaveli C, Farias A, Renno M, Boechat N . Phenylhydrazides as inhibitors of Leishmania amazonensis arginase and antileishmanial activity. Bioorg Med Chem. 2019; 27(17):3853-3859. DOI: 10.1016/j.bmc.2019.07.022. View

5.
Ilari A, Fiorillo A, Genovese I, Colotti G . Polyamine-trypanothione pathway: an update. Future Med Chem. 2016; 9(1):61-77. DOI: 10.4155/fmc-2016-0180. View